

# Marc Michel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7096028/publications.pdf>

Version: 2024-02-01

49  
papers

6,049  
citations

185998

28  
h-index

205818

48  
g-index

52  
all docs

52  
docs citations

52  
times ranked

6239  
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. <i>Haematologica</i> , 2022, 107, 1698-1702.	1.7	18
2	Adult Evans' Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 381-392.	0.9	6
3	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. <i>Immunity</i> , 2022, 55, 1096-1104.e4.	6.6	42
4	De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. <i>Blood</i> , 2022, 139, 2561-2565.	0.6	12
5	High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
6	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Scientific Reports</i> , 2022, 12, 7140.	1.6	45
7	Misdiagnosed thrombocytopenia in children and adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. <i>Blood Advances</i> , 2021, 5, 1617-1626.	2.5	11
8	Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	40
9	Epidemiology of autoimmune hemolytic anemia: A nationwide population-based study in France. <i>American Journal of Hematology</i> , 2021, 96, E291-E293.	2.0	10
10	Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. <i>Haematologica</i> , 2021, 106, 3198-3201.	1.7	20
11	Evans syndrome in adults: an observational multicenter study. <i>Blood Advances</i> , 2021, 5, 5468-5478.	2.5	21
12	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
13	Characteristics and Outcome of Adults with Severe Autoimmune Hemolytic Anemia Admitted in Intensive Care Unit: Results from a Large French Observational Study. <i>Blood</i> , 2021, 138, 930-930.	0.6	1
14	Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study. <i>Blood</i> , 2021, 138, 349-349.	0.6	6
15	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. <i>Blood Reviews</i> , 2020, 41, 100648.	2.8	267
16	Evans's Syndrome: From Diagnosis to Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 3851.	1.0	50
17	Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. <i>Blood</i> , 2020, 136, 2290-2295.	0.6	251
18	Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. <i>Blood</i> , 2020, 136, 3056-3061.	0.6	42

#	ARTICLE	IF	CITATIONS
19	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. <i>BMJ, The</i> , 2020, 369, m1844.	3.0	355
20	Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. <i>Haematologica</i> , 2020, 105, 2694-2697.	1.7	23
21	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up. <i>Blood</i> , 2020, 136, 24-25.	0.6	3
22	Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP Ritux. <i>American Journal of Hematology</i> , 2019, 94, 1314-1324.	2.0	55
23	Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. <i>British Journal of Haematology</i> , 2019, 187, 124-128.	1.2	29
24	Autologous <sup>111</sup> Indium Oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2019, 186, e44-e47.	1.2	8
25	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3780-3817.	2.5	593
26	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , 2019, 6, e48-e57.	2.2	195
27	Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study. <i>Blood</i> , 2019, 134, LBA-2-LBA-2.	0.6	9
28	Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study. <i>Blood</i> , 2019, 134, 2358-2358.	0.6	0
29	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	2.0	56
30	Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. <i>Rheumatology</i> , 2018, 57, 1432-1438.	0.9	38
31	Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. <i>British Journal of Haematology</i> , 2017, 177, 751-758.	1.2	24
32	A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm autoimmune hemolytic anemia in adults (the RAIHA study). <i>American Journal of Hematology</i> , 2017, 92, 23-27.	2.0	84
33	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. <i>American Journal of Hematology</i> , 2016, 91, E499-E501.	2.0	20
34	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	3.0	40
35	A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimmune Hemolytic Anemia in Adults. <i>Blood</i> , 2015, 126, 3338-3338.	0.6	1
36	Portal or Splenic Vein Thrombosis after Splenectomy for Immune Cytopenia: A Retrospective Cohort Study. <i>Blood</i> , 2015, 126, 3483-3483.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. American Journal of Hematology, 2014, 89, E150-5.	2.0	111
38	Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. American Journal of Hematology, 2014, 89, 194-198.	2.0	40
39	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 2014, 124, 3228-3236.	0.6	142
40	B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. Journal of Clinical Investigation, 2013, 123, 432-442.	3.9	154
41	Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Review of Hematology, 2011, 4, 607-618.	1.0	103
42	Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. British Journal of Haematology, 2011, 155, 498-508.	1.2	125
43	Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases. American Journal of Hematology, 2009, 84, 153-157.	2.0	90
44	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	0.6	2,128
45	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood, 2009, 114, 3167-3172.	0.6	216
46	Impact of Pregnancy On the Course of Immune Thrombocytopenic Purpura: An Observational Study On 44 Cases.. Blood, 2009, 114, 1320-1320.	0.6	2
47	Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood, 2008, 112, 999-1004.	0.6	227
48	Autoimmune Thrombocytopenic Purpura and Common Variable Immunodeficiency. Medicine (United Tj ETQqO 0 0.rgBT /Overlock 10 T	0.4	153
49	Platelet autoantibodies and lupus-associated thrombocytopenia. British Journal of Haematology, 2002, 119, 354-358.	1.2	49